Core Viewpoint - The company is strategically acquiring Jilin Youben to enhance its capabilities in African swine fever vaccine research and production, aiming to increase market share and core competitiveness in the animal vaccine sector [1]. Group 1: Acquisition and Strategic Goals - The acquisition of Jilin Youben is aimed at improving the speed of research and production transformation for African swine fever vaccines [1]. - The company plans to expand its market share in the animal vaccine field through this acquisition [1]. Group 2: Compliance and Safety Upgrades - Jilin Youben and Jinhe Youben have upgraded their facilities to meet the safety requirements for vaccine production and testing, achieving biosafety level three compliance by specific dates in 2025 [1]. - By the end of Q3 2025, the company will have met all necessary qualifications for conducting clinical trials for the African swine fever vaccine [1]. Group 3: Challenges in Vaccine Development - Jilin Youben is facing challenges in finalizing a technology licensing contract with the patent transferor, which is crucial for the production and testing of the African swine fever vaccine [2]. - The company has recognized the high technical difficulty and lengthy regulatory approval process associated with African swine fever vaccine development, leading to uncertainties in project timelines and performance [2]. - As a result of these challenges, the company has decided to suspend the research and application of the freeze-dried inactivated African swine fever vaccine [2].

Group 1 - The first African swine fever subunit vaccine in China has been approved for clinical trials [1] - The approval was granted to China National Pharmaceutical Group Animal Health Co., Ltd. (referred to as "China National Animal Health") [1] - This marks a significant advancement in the research and development of African swine fever vaccines by China National Animal Health [1]